New drug combination delayed disease progression for subgroup of women with metastatic breast cancer
Dasatinib is approved by the U.S. …
Dasatinib is approved by the U.S. …
In a new phase 2 trial, patients treated with bortezomib had lower rates of severe acute GVHD and treatment-related mortality, and experienced better one-year overall survival than has been seen historically with such patients receiving standard preventive therapy, the investigators reported at the American Society of Hematology annual meeting. …